false 0001840425 0001840425 2024-10-04 2024-10-04 0001840425 blacu:UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member 2024-10-04 2024-10-04 0001840425 us-gaap:CommonStockMember 2024-10-04 2024-10-04 0001840425 blacu:RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member 2024-10-04 2024-10-04 0001840425 blacu:RightToReceiveOnetenth110OfOneShareOfCommonStockMember 2024-10-04 2024-10-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2024

 

 

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-41390   84-5052822
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code (425) 635-7700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Units, each consisting of one share of common stock, one redeemable warrant and one right   BLACU   The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share   BLAC   The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   BLACW   The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock   BLACR   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on February 15, 2024, the Company received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “Minimum Public Holders Requirement”). On April 1, 2024, the Company submitted to Nasdaq a plan to regain compliance with the Minimum Public Holders Requirement and, on April 17, 2024, the staff of Nasdaq approved the plan and granted the Company an extension until August 13, 2024 to demonstrate compliance with the Minimum Public Holders Requirement (the “Compliance Period”).

On August 20, 2024, the Company received written notice (the “Second Notice”) from Nasdaq stating that the Company has not regained compliance with the Minimum Public Holders Requirement within the Compliance Period. In accordance with the Second Notice, the Company timely requested a hearing before the Hearings Panel (the “Panel”), which automatically stayed any suspension or delisting action of the Company’s securities, and the hearing was held on October 1, 2024. On October 4, 2024, the Panel granted the Company’s request for continued listing on the Nasdaq, subject to the requirement that on or before February 17, 2025, the Company shall demonstrate compliance with Listing Rule 5505, and that during the exception period, the Company shall provide prompt notification of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 10, 2024

 

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
By:  

/s/ Kuk Hyoun Hwang

  Name: Kuk Hyoun Hwang
  Title: Chief Executive Officer
v3.24.3
Document and Entity Information
Oct. 04, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001840425
Document Type 8-K
Document Period End Date Oct. 04, 2024
Entity Registrant Name BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Entity Incorporation State Country Code DE
Entity File Number 001-41390
Entity Tax Identification Number 84-5052822
Entity Address, Address Line One 10900 NE 4th Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Bellevue
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98004
City Area Code (425)
Local Phone Number 635-7700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Units, each consisting of one share of common stock, one redeemable warrant and one right
Trading Symbol BLACU
Security Exchange Name NASDAQ
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol BLAC
Security Exchange Name NASDAQ
Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
Trading Symbol BLACW
Security Exchange Name NASDAQ
Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Right to receive one-tenth (1/10) of one share of common stock
Trading Symbol BLACR
Security Exchange Name NASDAQ
Bellevue Life Sciences A... (NASDAQ:BLACW)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Bellevue Life Sciences A...
Bellevue Life Sciences A... (NASDAQ:BLACW)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Bellevue Life Sciences A...